Halozyme posts FY2025 royalty revenue of USD 868 million, up 52%

Reuters

02/18

Halozyme posts FY2025 royalty revenue of USD 868 million, up 52%

Halozyme Therapeutics Inc. reported full year (FY) 2025 total revenue of USD 1.40 billion, up 38%. Royalty revenue reached a record USD 868 million, an increase of 52%. Product sales, net, totaled USD 376 million. The company completed acquisitions of Elektrofi’s Hypercon technology and Surf Bio’s Hyperconcentration Technology during the period. For FY 2026, Halozyme reiterated its financial guidance, expecting total revenue between USD 1.71 billion and USD 1.81 billion, adjusted EBITDA between USD 1.13 billion and USD 1.21 billion, and non-GAAP diluted EPS between USD 7.75 and USD 8.25.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171601PR_NEWS_USPR_____LA89718) on February 17, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2612467022"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612467022\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612467022?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612467022","market":"fut","top_or_hot":-1,"title":"Halozyme posts FY2025 royalty revenue of USD 868 million, up 52%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Halozyme posts FY2025 royalty revenue of USD 868 million, up 52%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported full year (FY) 2025 total revenue of USD 1.40 billion, up 38%. Royalty revenue reached a record USD 868 million, an increase of 52%. Product sales, net, totaled USD 376 million. The company completed acquisitions of Elektrofi’s Hypercon technology and Surf Bio’s Hyperconcentration Technology during the period. For FY 2026, Halozyme reiterated its financial guidance, expecting total revenue between USD 1.71 billion and USD 1.81 billion, adjusted EBITDA between USD 1.13 billion and USD 1.21 billion, and non-GAAP diluted EPS between USD 7.75 and USD 8.25.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171601PR_NEWS_USPR_____LA89718) on February 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme posts FY2025 royalty revenue of USD 868 million, up 52%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme posts FY2025 royalty revenue of USD 868 million, up 52%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Halozyme posts FY2025 royalty revenue of USD 868 million, up 52%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. reported full year (FY) 2025 total revenue of USD 1.40 billion, up 38%. Royalty revenue reached a record USD 868 million, an increase of 52%. Product sales, net, totaled USD 376 million. The company completed acquisitions of Elektrofi’s Hypercon technology and Surf Bio’s Hyperconcentration Technology during the period. For FY 2026, Halozyme reiterated its financial guidance, expecting total revenue between USD 1.71 billion and USD 1.81 billion, adjusted EBITDA between USD 1.13 billion and USD 1.21 billion, and non-GAAP diluted EPS between USD 7.75 and USD 8.25.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171601PR_NEWS_USPR_____LA89718) on February 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL5ZYyz4:1","article_id":"2612467022","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612467022","pubTimestamp":1771362120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Halozyme Therapeutics Inc. reported full year  2025 total revenue of USD 1.40 billion, up 38%. Royalty revenue reached a record USD 868 million, an increase of 52%. Product sales, net, totaled USD 376 million. The company completed acquisitions of Elektrofi’s Hypercon technology and Surf Bio’s Hyperconcentration Technology during the period. For FY 2026, Halozyme reiterated its financial guidance, expecting total revenue between USD 1.71 billion and USD 1.81 billion, adjusted EBITDA between USD 1.13 billion and USD 1.21 billion, and non-GAAP diluted EPS between USD 7.75 and USD 8.25.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","HALO":"奥洛兹美医疗","BK4139":"生物科技"},"translate_title":"Halozyme公布2025财年特许权使用费收入为8.68亿美元，增长52%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9},"content_text":"Halozyme posts FY2025 royalty revenue of USD 868 million, up 52%\n    \n\n        Halozyme Therapeutics Inc. reported full year (FY) 2025 total revenue of USD 1.40 billion, up 38%. Royalty revenue reached a record USD 868 million, an increase of 52%. Product sales, net, totaled USD 376 million. The company completed acquisitions of Elektrofi’s Hypercon technology and Surf Bio’s Hyperconcentration Technology during the period. For FY 2026, Halozyme reiterated its financial guidance, expecting total revenue between USD 1.71 billion and USD 1.81 billion, adjusted EBITDA between USD 1.13 billion and USD 1.21 billion, and non-GAAP diluted EPS between USD 7.75 and USD 8.25.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602171601PR_NEWS_USPR_____LA89718) on February 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}